Ischemic vascular endothelium and microvasculature

Ischemic vascular endothelium and microvasculature refers to the specialized cellular lining of the smallest blood vessels when subjected to restricted blood supply and subsequent oxygen deprivation (PMID: 25635381). Under ischemic conditions, the endothelium undergoes significant structural and functional transformations, including the loss of barrier integrity and increased permeability (StatPearls: Endothelial Dysfunction). It also involves the increased expression of cell adhesion molecules like ICAM-1 and VCAM-1, which facilitate leukocyte recruitment and inflammation (PMID: 11518375). This state is a critical component of various pathological conditions such as myocardial infarction, ischemic stroke, and peripheral artery disease (PMID: 30243158). While not a single molecular target, it represents a complex physiological environment characterized by the upregulation of specific proteins like Hypoxia-Inducible Factor 1-alpha (HIF-1α) and Vascular Endothelial Growth Factor (VEGF) (UniProt: P41222, P15692). These molecular changes serve as adaptive responses to hypoxia but can also contribute to tissue damage if prolonged. Therapeutic strategies often focus on restoring blood flow through thrombolysis or protecting the endothelial barrier from reperfusion injury (PMID: 21907178). Additionally, researchers are utilizing the unique molecular signatures of ischemic vessels for targeted drug delivery using ligands that bind to upregulated endothelial markers (PMID: 28683340). Understanding the microvascular response to ischemia is essential for developing treatments that mitigate secondary injury and promote functional recovery. Overall, the ischemic endothelium acts as both a barrier to and a facilitator of therapeutic intervention in vascular diseases.

Other names

Ischemic endotheliumHypoxic microvasculatureIschemic microvesselsIschemic vascular bed

Thrombolysis through the conversion of plasminogen to plasmin, inhibition of platelet aggregation via GP IIb/IIIa blockade, and endothelial stabilization through HMG-CoA reductase inhibition.